Schroders Capital Global Innovation Trust : INOV

19 Sep 2025 2 min read

Morning briefing: Knockout bid for 89Bio boosts International Biotechnology; plus MCT, NCYF, FGEN & INOV

International Biotechnology Trust enjoys another premium takeover for one of its companies; there are results from Middlefield Canadian, New City High Yield and Schroders Capital Global Innovation; and Foresight Environmental Infrastructure clears its discontinuation vote. International Biotechnology Trust (IBT) says 89Bio, a US Nasdaq-listed company accounting for 0.5% of its £230m portfolio, yesterday received a […]

26 Aug 2025 2 min read

Morning briefing: Literacy Capital shifts to “maximising value”; Riverstone Energy shareholders back wind-up; plus WHR, BGS, INOV, BSV, BSC, CRWC, AAEV & AATG

Our morning roundup sees UK private equity fund Literacy Capital issue half-year results and Riverstone Energy receive overwhelming shareholder support for a gradual wind-down. Literacy Capital (BOOK), the £233m UK private equity fund trading on a 25% discount, says it is “rebalancing our emphasis from new investments, towards building and maximising value from our current […]

08 Aug 2025 4 min read

Trust Spot: July’s biggest risers and fallers leave one 9%-yielding property fund cheap on a 19% discount

Private equity, technology, biotech and emerging markets trusts rallied in July, but several funds in wind-down wobbled. Our monthly roundup of the biggest investment company risers and fallers highlights one UK real estate trust offering a cash-covered 9% dividend yield on an attractive discount. Private equity, tech and EM funds rally Welcome to our new-look […]

05 Aug 2025 2 min read

FCA fines Neil Woodford £5.9m for his fund’s 2019 collapse that left Patient Capital trust in the lurch

The Financial Conduct Authority bans former star fund manager from running retail funds or holding senior management roles in the City and imposes a £40m fine on his former business Woodford Investment Management. The £5.9m penalty for Woodford and a £40m fine for his former business Woodford Investment Management (WIM) comes six years after the […]

25 Jul 2025 1 min read

Investors jump at chance to sell what’s left of Woodford Patient Capital Trust

Investors holding more than two thirds of Schroders Capital Global Innovation applied to sell their shares in this month’s tender offer. The £37m tender offer of Schroders Capital Global Innovation (INOV) was oversubscribed by more than three times as investors leaped at the chance to exit the former Woodford Patient Capital Trust at asset value. […]

11 Jul 2025 2 min read

Morning briefing 11 July: ASLI, SERE, CREI, INOV, CGEO

Abrdn European Logistics Income sells over £57m of properties in its managed wind-down and promises a return of capital next month once further disposals are made. Plus news from Schroder European Real Estate, Custodian Property Income, Georgia Capital and a reminder from Schroders Capital Global Innovation of this month’s £37m tender offer.

04 Jul 2025 5 min read

Q&A: Should I finally sell my shares in the great Woodford wind-up, Schroders Capital Global Innovation (INOV)?

The former Woodford Patient Capital Trust is winding down and returning £37m to its long-suffering shareholders in a ‘tender offer’ this month. Should they sell some, all or none of their shares? The situation is not straightforward as, despite its historic problems, the investment trust has backed some valuable companies under its current managers at […]

19 Jun 2025 1 min read

Schroder Capital Global Innovation launches tender offer

Following the approval of its managed wind down in February 2025, Schroder Capital Global Innovation is ready to start handing back some money to shareholders. With the cash that the trust already had, the realisation of Araris Biotech in April and an anticipated partial realisation of the company’s interests in AI Company II, there is […]

22 May 2025 2 min read

QuotedData’s morning briefing 22 May 2025 – FJV, PCGH, GRID, INOV, SERE

In QuotedData’s morning briefing 22 May 2025: We also have: Did you miss from yesterday?

28 Mar 2025 2 min read

Schroders Capital Global Innovation begins wind-down as NAV falls 21.2%

Schroders Capital Global Innovation Trust (INOV) has published its annual results for the year ended 31 December 2024. The period marked a pivotal shift in strategy, with shareholders voting overwhelmingly in favour of a managed wind-down at a general meeting in February 2025. The trust’s NAV fell by 21.2% over the year to 19.94p per […]

31 Jan 2025 1 min read

Schroders Capital Global Innovation publishes wind down proposals

Further to its announcement of 4 December 2024, that it was bringing forward its continuation vote in order to provide clarity on the future of the company at the earliest opportunity (click here to see our coverage of that announcement), Schroders Capital Global Innovation (INOV) has now published a circular. A general meeting is being […]

04 Dec 2024 3 min read

QuotedData’s morning briefing 4 December 2024 – ARR, SEIT, PNL, MNKS, INOV

In QuotedData’s morning briefing 4 December 2024: Aurora UK Alpha (ARR) announced that following the proposed combination with Artemis Alpha Trust, it has changed its name to Aurora UK Alpha plc. The company will continue to trade under the ticker ARR. SDCL Energy Efficiency Income (SEIT) announced its interim results for the six months to […]

30 Aug 2024 1 min read

QuotedData’s weekly news show 30th August 2024

Thank you to everyone that listened in today on our YouTube channel. In this week’s show, Matthew Read covered the week’s top stories: Renewables/infrastructure (0:39, 2:25) Octopus Renewables Infrastructure (1:18) ATS/INOV – Reaction engines (4:34) PRS REIT – Requisition request (5:58) This week’s interview was with James Harries from STS Global Income & Growth Trust – watch […]

20 Jun 2024 2 min read

Syncona backs two new cancer companies

Syncona has added two new companies to its portfolio, iOnctura and Yellowstone Biosciences. Syncona has invested €30m (£25.7m) in iOnctura, an innovative, clinical-stage, small molecule company combating neglected and hard-to-treat cancers, and launched Yellowstone, a new oncology company pioneering soluble bispecific T-cell receptor (TCR)-based therapies, with a £16.5m commitment. iOnctura iOnctura is developing selective cancer […]

23 May 2024 1 min read

QuotedData’s morning briefing 23 May 2024 – BGLF, CRS, INOV, IPU

In QuotedData’s morning briefing 23 May 2024: Blackstone Loan Financing (BGLF) will hand back €23m to its shareholders by way of a compulsory partial redemption of up to 24,779,142 shares on 10 June 2024. On this basis, a holder of 10,000 shares will have 559 shares redeemed, and receive €518.86 in cash. Crystal Amber (CRS) […]

28 Mar 2024 1 min read

Schroder Capital Global Innovation encouraged by positive Q4 move

Schroder Capital Global Innovation reports an 11.2% fall in its NAV over 2023, but is encouraged by the positive NAV move in the final quarter of the year. The share price fell by 5.3% as the discount narrowed, helped by buying back 45.1m shares. The negative performance during the first three quarters of the year […]

13 Feb 2024 2 min read

QuotedData’s morning briefing 13 February 2024 – JGGI, TRIG, INOV, BPCR

In QuotedData’s morning briefing 13 February 2024: JPMorgan Global Growth & Income (JGGI) announced a placing and retail offer of shares in light of the ongoing demand in the market (with a total of 50,975,336 JGGI shares being issued over the last 12 months) and a recent approach by a large wealth manager who has […]

09 Feb 2024 2 min read

QuotedData’s morning briefing 9 February 2024 – INOV, RTW, ADIG

In QuotedData’s morning briefing 9 February 2024: Schroders Capital Global Innovation Trust (INOV) has invested US$1.6m in Neurona Therapeutics through its Series E financing round, which raised US$120m. The fundraising was co-led by Viking Global Investors and Cormorant Asset Management with participation from new and existing investors including The Column Group, Passaic Capital Management, Lyfe […]

05 Feb 2024 2 min read

QuotedData’s morning briefing 5 February 2024 – CVCE, INOV, PEY, GSF, HGT, SEIT

In QuotedData’s morning briefing for 5 February 2024: CVC Income & Growth (CVCE) has announced an increase in its annual dividend targets, increased to 8.25p per ordinary sterling share and 7.25c per ordinary euro share. This means that CVCE’s quarterly dividends will be increased to 2.0625p per sterling share and 1.8125c per euro share. Schroders […]

08 Dec 2023 1 min read

Schroders Capital Global Innovation’s Carmot Therapeutics sold to Roche

Schroders Capital Global Innovation (INOV) has announced that its portfolio company Carmot Therapeutics Inc., a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, entered into a definitive agreement to be acquired by Roche, on 3 December 2023. Roche is acquiring Carmot at a purchase price […]

04 Dec 2023 3 min read

QuotedData’s morning briefing 4 December 2023 – GSF, SEQI, SYNC, SBO, INOV, IGC, JLEN, SEIT

In QuotedData’s morning briefing 4 December 2023: Gore Street Energy Storage Fund (GSF) has announced that its investment manager, Gore Street Capital, has been selected as the co-manager of Japan’s first dedicated fund for grid storage batteries, with the Tokyo Metropolitan Government as the cornerstone investor, contributing £10.6m to the fund. Sequoia Economic Infrastructure Income Fund […]

20 Nov 2023 1 min read

QuotedData’s morning briefing 20 November 2023 – SSIT, INOV, IBT, USF, UKCM

In QuotedData’s morning briefing 20 November 2023: Seraphim Space Investment Trust (SSIT) has released its Q1 update. Highlights include a further £4.1m, invested in two projects over the quarter. Portfolio value increased to £199.9m up £12.4m, due to a combination of additional investments, unrealised fair value net gains and an unrealised FX gain. The main […]

15 Nov 2023 2 min read

QuotedData’s morning briefing 15 November 2023 – GCP, FP, INOV, WHR

QuotedData’s morning briefing 15 November 2023: GCP Infrastructure Investments (GCP) has released a quarterly update to 30 September 2023. NAV total return over the period was 1.4% while shares fell 11.6%, widening the fund’s discount which now sits at 36%. During the quarter, the company completed a refinancing of two existing loan notes secured against […]

09 Nov 2023 1 min read

Schroder Cap Global Innovation backs Bizongo

Schroders Capital Global Innovation Trust has made an investment of $8.0m in an India-based vendor digitisation company, Bizongo. This investment formed part of the company’s $50.0m Series E funding round that was led by Schroders Capital with participation from other investors including IFC, BCap, Chiratae Ventures, and British International Investment. What is vendor digitisation? I […]

03 Nov 2023 1 min read

QuotedData’s morning briefing 3 November 2023 – INOV

In QuotedData’s morning briefing 3 November 2023: Schroders Capital Global Innovation (INOV) has made an investment in US-based cybersecurity company, Securiti which it describes as “the pioneer of the Data Command Center, a centralized platform that enables the safe use of data and GenAI”. Its platform unifies controls for data security, privacy, governance and compliance […]

07 Sep 2023 1 min read

Schroders Capital Global Innovation NAV dives again

Schroders Capital Global Innovation Trust says that its NAV as of 30 June 2023 was 24.73p per share, a decrease of 6.1% relative to the NAV per share as of 31 March 2023 (26.35p) and a decrease of 5.4% relative to the indicative unaudited NAV per share as of 30 June 2023 published on 3 […]

21 Jul 2023 5 min read

QD view – Where there’s smoke is there fire?

We have previously espoused the notion that the widespread discounts in the unlisted investment trust sectors are often unjustified. It is certainly true that many viable investment strategies are trading on ever wider discounts, if not their historically widest levels, with investors for example selling down their holdings out of fear of valuations cuts, or […]

09 Jun 2023 3 min read

QD view – AI mania driving tech recovery

Big getting bigger One of the dominant, and for most investment managers highly frustrating, trends of recent times has been the strength of the mega caps. It was really evident in the UK last year, where a handful of large stocks drove indices higher and, if you were underweight those, as most active managers would […]

06 Jun 2023 1 min read

QuotedData’s morning briefing 6 June 2023

Marwyn Value Investors (MVI) announced the appointment of Will Self to the company’s board as CEO, leading the development and execution of MVI’s overall company strategy. James Corsellis, CIO commented: “We are delighted to be working with Will in his new role as CEO, alongside Mark Hodges as chairman, as the company continues in the […]

17 Apr 2023 4 min read

SUPP struggles against market headwinds

Schroder UK Public Private Trust (SUPP) has reported annual results for its financial year ending 31 December 2022. SUPP has reported a NAV total return of -40.7% and a share price return of -53.3%. SUPP’s negative returns were driven predominantly by its largest holding, Oxford Nanopore, whose share price fell by 64.6%, having IPOed earlier […]

06 Apr 2023 2 min read

Schroder UK Public Private backs Indian AgTech start-up

Schroder UK Public Private Trust is making its first transaction in Asia, with an investment of $8.0m (about £6.6m) in AgroStar (Ulink Agritech Pvt. Ltd.), one of India’s foremost agricultural technology (AgTech) start-ups. You can visit its website here. This investment forms part of a $25m (£20.6m) total investment by Schroders Capital that led the […]

15 Mar 2023 2 min read

SBV updates from Schroder UK Public Private and Seraphim Space

Seraphim Space (SSIT) has commented on the recent events concerning Silicon Valley Bank (SVB). SSIT confirms that it does not bank with SVB, nor does its investment manager, Seraphim Space Manager LLP. However, eight of SSIT’s portfolio companies use SVB as their primary banking provider. SSIT says that it does not anticipate that the recent […]

17 Nov 2022 1 min read

QuotedData’s morning briefing 17 November 2022

In QuotedData’s morning briefing 17 November 2022: As interest rates continue to climb, NB Global Monthly Income Fund (NBMI) is increasing its dividend once again. The target distribution for the remainder of 2022 is a rate of 8.10% of NAV each year (net of fees and expenses) which equates to a target monthly distribution for […]

04 Nov 2022 2 min read

QuotedData’s morning briefing 4 November 2022

In QuotedData’s morning briefing 4 November 2022: Castelnau Group (CGL) has made a further investment in Ocula Technologies Holdings Ltd, a data sciences business in which it owns a majority stake. The additional investment of approximately £700,000 is part of a proposed additional funding round which it is hoped will see new, third-party investors become […]

31 Oct 2022 1 min read

Schroder UK Public Private Trust invests in antibody drug firm

Schroder UK Public Private Trust (SUPP) has announced that it has made a commitment of CHF 3m (£2.7m) to antibody-drug conjugates (ADCs) development company, Araris Biotech AG, as part of its CHF 23.5m (£21.4m,) financing round. Araris is pioneering the development of a novel antibody-drug conjugate ADC-linker technology to enable efficient and precise production of […]

30 Sep 2022 5 min read

QuotedData’s morning briefing 30 September 2022

In QuotedData’s morning briefing 30 September 2022: NextEnergy Solar Fund (NESF) has announced that it has increased the commitments available under its Revolving Credit Facility (RCF) with AIB Group (UK) Plc and NatWest from £75m to £135m – an increase of £60m. The additional commitments have been agreed at a margin of 120bps over SONIA […]

21 Sep 2022 2 min read

QuotedData’s morning briefing 21 September 2022

In QuotedData’s morning briefing 21 September 2022: Henderson High Income (HHI) produced returns in line with its benchmark (80% All-Share Index/20% ICE BofAML Sterling Non-Gilts Index) over the six months ended 30 June 2022, both returning -6.1%. It helped that UK equities beat bonds over the period as the trust began the year with an […]

27 Apr 2022 1 min read

QuotedData’s morning briefing 27 April 2022

In QuotedData’s morning briefing 27 April 2022: Schroder UK Public Private (SUPP) holding BenevolentAI has completed its business combination with Odyssey Acquisition, a Euronext Amsterdam-listed investment company. Assuming sufficient secondary market liquidity, BenevolentAI will be valued using its unadjusted quoted price which will be reflected in the company’s daily indicative unaudited NAV per share as […]

21 Apr 2022 2 min read

Schroder UK Public Private considers going global

Schroder UK Public Private says that over the course of 2021, it generated an NAV total return of 37.4%. However, the share price rose by just 6.8%. The board is considering its options to narrow the discount, including using share buybacks. More cash is available to fund these now – gearing was cut over the […]

05 Apr 2022 2 min read

QuotedData’s morning briefing 5 April 2022

In QuotedData’s morning briefing 5 April 2022: Digital 9 Infrastructure (DGI9) has completed the acquisition of Leeson Telecom (Host Ireland), a leading enterprise broadband provider in Greater Dublin. The purchase price was about €60m. Host Ireland owns and operates the highest capacity licensed microwave-based Fixed Wireless Access network in Greater Dublin. It provides high quality, […]

03 Mar 2022 1 min read

Schroder UK Public Private backs Epsilogen

Schroder UK Public Private backs Epsilogen – Schroder UK Public Private Trust has made a £3.0m investment in a leading immunoglobulin E (“IgE”) antibodies developer, Epsilogen, as part of that company’s £30.75m Series B funding round. The funding round was led by a new investor, Novartis Venture Fund, and joined by new investors 3B Future […]

24 Feb 2022 2 min read

QuotedData’s morning briefing 24 February 2022

In QuotedData’s morning briefing 24 February 2022: Pantheon International (PIN) has posted its interim results for the six months to 30 November 2021. Over the period, the trust delivered 22.1% NAV increase and a 17.6% increase in its share price, while it continued to benefit from a supportive exit environment with realisations primarily to strategic […]

12 Jan 2022 2 min read

QuotedData’s morning briefing 12 January 2022

In QuotedData’s morning briefing 12 January 2022: ICG Longbow Senior Secured UK Property Debt Investments (LBOW) has received repayment in full of the £16.2m GMG loan, following a sale of the underlying property. The repayment is accompanied by interest and exit fees of approximately £800,000 in aggregate. The board is consequently pleased to announce that […]

16 Dec 2021 2 min read

Schroder UK Public Private loans money to Rutherford Health

Schroder UK Public Private loans money to Rutherford Health – Schroder UK Public Private Trust has committed £3m towards an £8m bridge loan being provided to Rutherford Health by its shareholders. In addition, LF Equity Income Fund has committed to provide a convertible loan facility of £2m. The loan will accrue interest at the rate […]

06 Dec 2021 1 min read

Schroder UK Public Private’s Benevolent AI in SPAC deal

Schroder UK Public Private’s Benevolent AI in SPAC deal – Schroder UK Public Private (SUPP) holding BenevolentAI has entered into a definitive agreement for a business combination with Odyssey Acquisition, a Euronext Amsterdam-listed investment company – and a special purpose acquisition company or SPAC. The combination will be effected by way of a share exchange […]

02 Dec 2021 3 min read

QuotedData’s morning briefing 2 December 2021

In QuotedData’s morning briefing 2 December 2021: ICG Enterprise Trust (ICGT) is investing in European Camping Group alongside funds advised by PAI Partners. The investment is being led by PAI Europe VII. ICGT will invest as a limited partner in that fund and also through a direct co-investment. Altogether, ICGT’s investment will be about €11.2m. European Camping […]

18 Nov 2021 1 min read

Schroder UK Public Private backs Attest

Schroder UK Public Private backs Attest – Schroder UK Public Private Trust has made a $7.0m investment in market research technology platform, Attest Technologies, as part of that company’s $64m Series B funding round. The investment in Attest is the third new private equity investment since the appointment of Schroder Investment Management as manager. Attest is […]

21 Sep 2021 1 min read

Change of manager for Schroder UK Public Private

Schroder UK Public Private saw its NAV rise by 16.1% to 40.65p over the six months ended 30 June. As we reported last week, the upcoming IPO of Oxford Nanopore could see this rise further. In the private equity portfolio two new investments were made into Tessian and Revolut. The portfolio had 34 holdings, 25 […]

17 Sep 2021 1 min read

QuotedData’s weekly news show 17 September 2021

QuotedData’s weekly news show 17 September 2021 Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on YouTube. In this week’s show, James Carthew covered the week’s top stories: GCP Asset Backed Income Schroder UK Public Private Apax Global Alpha This week’s interview was with Robin Parbrook […]

2 min read

QD view – private equity – silly cheap

As we discussed in Friday’s news show, it has been a good week for private equity investors. Hg Capital said it had sold its investment in supply chain management software company Achilles at a 20% premium to its last valuation, adding 0.9% to NAV. Apax Global Alpha announced an 89% uplift in the value of […]

16 Sep 2021 1 min read

Schroder UK Public Private to benefit from Oxford Nanopore IPO?

Schroder UK Public Private to benefit from Oxford Nanopore IPO? – Schroder UK Public Private has highlighted that its portfolio company Oxford Nanopore Technologies Limited has today filed notice of its intention to float. As part of the potential IPO, it is expected that the company will include a limited secondary offer of £300m, half […]

09 Aug 2021 2 min read

QuotedData’s morning briefing 9 August 2021

In QuotedData’s morning briefing 9 August 2021: Schroder UK Public Private (SUPP) has made a $13.7m investment in neobank, Revolut, as part of the business’ $800m Series E funding round which values it at $3bn. The investment is in line with SUPP’s focus on backing innovative businesses founded in the UK with disruptive innovations, significant global growth potential, […]

21 Jun 2021 3 min read

QuotedData’s morning briefing 21 June 2021

In QuotedData’s morning briefing 21 June 2021: JZ Capital Partners (JZCP) has sold its portfolio holding Salter Labs, for approximately $41m. The company’s interest in Salter Labs is currently valued at around $37.6m. Further proceeds of approximately $750,000 have also been placed in escrow whereby some or all, depending on the outcome of certain closing adjustments, […]

25 May 2021 1 min read

Schroder UK Public Private makes first new investment since manager’s December 2019 appointment

Schroder UK Public Private (SUPP) has announced a $6.75m investment into cybersecurity company, Tessian, as part of its $65m Series C funding round. We note that this represents the first new investment for SUPP since the appointment of Schroder Investment Management as manager on 13 December 2019, following the fallout from Woodford Patient Capital. Tessian […]

06 May 2021 1 min read

QuotedData’s morning briefing 6 May 2021

In QuotedData’s morning briefing 6 May 2021: Schroder UK Public Private says that Oxford Nanopore Technologies has raised £195m in new capital including £125m from some new investors – Temasek, Wellington Management, M&G Investments and Nikon. In addition, existing shareholders invested £70m. The valuation in the NAV as at 31 December 2020 was based on the […]

05 May 2021 3 min read

QuotedData’s morning briefing 5 May 2021

In QuotedData’s morning briefing 5 May 2021 – JLEN Environmental Assets (JLEN) announced a proposed placing for up to approximately 54.7m new ordinary shares. The shares are not being offered at a fixed price, but at a placing price per share, which will be determined by the bookbuild. The placing price will be agreed between […]

26 Apr 2021 4 min read

A tough 2020 for Schroder UK Public Private

Schroder UK Public Private (SUPP) released its annual results to 31 December 2020, with its NAV dropping by 29.2%. The shares were down 19.2%. In her last statement as chair of SUPP, the retiring Susan Searle noted: “The valuation at 31 December 2020 is clearly disappointing. During the year, the company’s quoted holdings saw a decline in […]

09 Apr 2021 1 min read

QuotedData’s weekly news show 9 April 2021

QuotedData’s weekly news show 9 April 2021 Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on Youtube. In this week’s show, James Carthew covered the week’s top stories: Schroder UK Public Private slashed the value of its Rutherford Health investment to £34m from £81m SDCL Energy Efficiency’s […]

1 min read

QuotedData’s morning briefing 9 April 2021

In QuotedData’s morning briefing 9 April 2021: Schroder UK Public Private says it has completed the sale of its shares in Kymab to Sanofi for approximately US$82m. There may be additional contingent payments of up to US$33m, subject to a deferred purchase price release and Kymab achieving certain development and regulatory milestones. Hibernia REIT says that it […]

08 Apr 2021 1 min read

QuotedData’s morning briefing 8 April 2021

In QuotedData’s morning briefing 8 April 2021: Schroder UK Public Private has slashed the value of its Rutherford Health investment to £34m from £81m. The statement says “The valuation of Rutherford Health has been reduced to reflect slower than expected commercial progress and increased risk to the business outlook for equity holders.” This offsets good news […]

15 Mar 2021 2 min read

QuotedData’s morning briefing 15 March 2021

In QuotedData’s morning briefing 15 March 2021 – International Biotechnology Trust’s (IBT’s) board and its manager, SV Health Investors, announced that Carl Harald Janson has decided to step back from his role as lead manager after seven at the helm. Lead responsibility for portfolio management will transition to Ailsa Craig and Marek Poszepczynski and the board […]

27 Jan 2021 2 min read

QuotedData’s morning briefing 27 January 2021

In QuotedData’s morning briefing 27 January 2021 – Henderson Smaller Companies (HSL) delivered total NAV and share price returns of 20.6% and 27.7% over its six-months interim results period to 30 November 2020. HSL said that its NAV performance was 6.3% ahead of the average of our peers in the AIC UK smaller companies sector. 3i […]

15 Jan 2021 1 min read

QuotedData’s weekly news show 15 January 2021

QuotedData’s weekly news show 15 January 2021 Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on Youtube. In this week’s show, James Carthew covered the week’s top stories: Schroder British Opportunities update Schroders UK Public Private update Executive order 13959 Gabelli Value Plus liquidation vote Watch […]

14 Jan 2021 2 min read

QuotedData’s morning briefing 14 January 2021

In QuotedData’s morning briefing 14 January 2021: Polar Capital Global Financials has published a circular to convene a meeting on 1 February at which shareholders will be asked to approve the issue of up to 70,375,000 shares from treasury without pre-emption (first offering them to existing shareholders). The shares will be issued at a premium and […]

11 Jan 2021 2 min read

Schroder UK Public Private gets uplift from Kymab deal

Schroder UK Public Private gets uplift from Kymab deal – Schroder UK Public Private Trust says that portfolio company Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, has announced its acquisition by Sanofi, a global biopharmaceutical company. Sanofi will acquire Kymab for an upfront payment […]

08 Oct 2020 1 min read

QuotedData’s morning briefing 8 October 2020

In QuotedData’s morning briefing 8 October 2020: Schroder UK Public Private Trust (formerly Woodford Patient Capital) acknowledges the potential uplift to its NAV to come from the merger of Seedrs and Crowdcube. Like Augmentum, Schroder UK Public Private is an investor in Seedrs. Hg Capital Trust has secured a £200m multicurrency revolving credit facility. this boosts available […]

30 Sep 2020 2 min read

QuotedData’s morning briefing 30 September 2020

In QuotedData’s morning briefing 30 September 2020: The growth capital sector company, Schroder UK Public Private (SUPP), released interim results to 30 June 2020. The NAV declined by 8.1% (the decline since 1 April has been 1.5%). The following is an extract from the accompanying manager’s report: “Over this reporting period, the impact of the […]

21 May 2020 1 min read

QuotedData’s morning briefing 21 May 2020

In QuotedData’s morning briefing 21 May 2020, as the UK government issues three-year debt with a negative yield: Electra NAV dives to 373p from 548p, hit by fall in value of Hotter Shoes and TGI Fridays. Hotter Shoes is looking to “right size the retail estate” – shut shops – once the lockdown eases. TGI Fridays […]

01 May 2020 7 min read

A disappointing year for Schroder UK Public Private Trust

Schroder UK Public Private Trust (SUPP – formerly Woodford Patient Capital Trust) has announced its annual results for the year ended 31 December 2019. It was a year of major change for the trust and one that its chairman, Susan Searle, describes as disappointing – its net asset value fell 49.3%, from 97.61p to 49.46p, […]

1 min read

QuotedData’s morning briefing 1 May 2020

So far, it’s been a very quiet day for news. Princess Private Equity has provided a covid-19 update. The key takeaway is that, given current uncertainty, it is cutting its dividend by half for FY2020 to €0.29 per share (FY2019: €0.58 per share). Intu has appointed David Hargrave, as “chief restructuring officer”. He will also […]

10 Jan 2020 2 min read

Biotech Growth tops bio-trust league with 47% NAV rise – updated

Biotech Growth tops bio-trust league with 47% NAV rise – Orbimed-managed Biotech Growth Trust (BIOG) recorded the rise 47% rise in NAV in 2019, representing the best performance of the 14 specialist biotech/pharma closed end investment vehicles monitored by Marten & Co. Biotech Growth’s rise in NAV was more than double that of the benchmark […]

13 Dec 2019 1 min read

QuotedData’s other news 13 December 2019

In QuotedData’s other news 13 December 2019 – Oryx International Growth (OIG) delivered NAV total returns of 9% over its interim period to 30 September 2019. During the same period, OIG said the relevant smaller companies’ index reported a decline of approximately 7%. The board of Schroder UK Public Private Trust, previously Woodford Patient Capital […]

04 Nov 2019 1 min read

Woodford Patient Capital slashes Industrial Heat value

Woodford Patient Capital slashes Industrial Heat value – The board of Woodford Patient Capital has been notified by Link Fund Solutions, that it intends to amend the valuations of two of the company’s holdings. The first is a downward revaluation to IH Holdings International Limited (Industrial Heat) reflecting a delay in operational progress, in respect of […]

16 Oct 2019 2 min read

Woodford Investment Management to close

Woodford Investment Management to close – The board of Woodford Patient Capital Trust (WPCT) announced last night that, in light of recent events, Woodford Investment Management Limited (WIM) had served notice of termination in relation to its role as manager. During its three-month notice period, the board said WIM has committed to work collaboratively throughout the […]

15 Oct 2019 1 min read

Neil Woodford no longer manager of Woodford Equity Income

Neil Woodford no longer manager of Woodford Equity Income: Woodford Patient Capital (WPCT) released the following statement: “The board of WPCT notes the statement by Link Fund Solutions Limited, the Authorised Corporate Director of the LF Woodford Equity Income Fund (WEIF), that: (i) the decision has been taken by LFS not to re-open WEIF and instead […]

30 Sep 2019 5 min read

Woodford Patient Capital reports interims

Woodford Patient Capital reports interims – Woodford Patient Capital has reported interim results to 30 June 2019. The company released the following: NAV of £654m as at 30 June 2019, following an interim review; Borrowings reduced to £111.1m as at 26 Sept 2019; Independent valuation review of the top 20 investments completed, following mandate from […]

26 Sep 2019 1 min read

Woodford Patient Capital slashes NAV again

Woodford Patient Capital slashes NAV again – the board of Woodford Patient Capital Trust has been notified by Link Fund Solutions Limited, that it intends to reduce the valuations of three of the company’s holdings. These valuation adjustments reflect the challenging fundraising environment for these businesses which may impact their ability to or the level […]

13 Sep 2019 1 min read

Woodford Patient Capital slashes NAV again

Woodford Patient Capital slashes NAV again – Woodford Patient Capital says it will cut its NAV once again. This time by 4p per share. Bizarrely, the announcement doesn’t tell investors why. The statement says – “Link Fund Solutions Limited (“Link”), through its Fair Value Pricing Committee, is responsible for the valuation of the portfolio of […]

06 Sep 2019 1 min read

Woodford Patient Capital wins concessions from lender

Woodford Patient Capital wins concessions from lender – Woodford Patient Capital has a borrowing facility for up to GBP150 million (the “Facility”) and is permitted under its investment policy to borrow up to 20 per cent. of net asset value at the time of borrowing. Borrowings as at 4 September 2019 were GBP113.7 million. While the […]

02 Sep 2019 1 min read

Jane Tufnell joins Woodford Patient Capital Trust’s board

Woodford Patient Capital Trust (WPCT) has announced the appointment of Jane Tufnell as an independent non-executive director with immediate effect. Jane will also become a member of the Audit, Risk and Valuation and Management Engagement Committees. Jane has considerable investment trust and fund management experience, including a number of board and non-executive roles. She has […]

23 Aug 2019 1 min read

Woodford watch – Patient Capital writes down NAV

Woodford watch – Patient Capital writes down NAV – Link Fund Solutions Limited, through its Fair Value Pricing Committee, is responsible for the valuation of the portfolio of Woodford Patient Capital Trust. Link, with the support of an independent valuation firm (IHS Markit), values Patient Capital’s unquoted assets in accordance with the Financial Reporting Standard (FRS) […]

31 Jul 2019 1 min read

QuotedData’s other news 31 July 2019

In QuotedData’s other news 31 July 2019: The multi-asset fund, Tetragon Financial Group (TFG) reported half-year results to 30 June 2019; total return NAV was up 14.3%. The company’;s allocation to TFG Asset Management (which owns Tetragon’s private equity investments in asset management companies) generated the largest gains in the portfolio during the period. We also […]

30 Jul 2019 1 min read

More woes for Woodford? Benevolent AI and Industrial Heat delist from TISE

Woodford Funds has issued a statement that Benevolent AI and Industrial Heat have delisted from The International Stock Exchange (TISE). These are major holdings in both the Woodford LF Equity Income Fund (a UCITS fund) and Woodford Patient Capital Trust (WPCT – a UK investment trust). While WPCT, with its closed ended structure, may suffer from […]

29 Jul 2019 2 min read

Woodford Patient Capital may fire Woodford

Woodford Patient Capital may fire Woodford – this morning the trust made the following announcement – “The Board of Woodford Patient Capital Trust plc (“WPCT” or the “Company”), as stated in the announcement on 28 June 2019, has been closely monitoring the situation at Woodford Investment Management Limited (the “Portfolio Manager”) and remains focused on […]

22 Jul 2019 1 min read

Woodford Patient Capital reportedly puts £10m into Atom Bank

Woodford Patient Capital reportedly puts £10m into Atom Bank Atom Bank has announced this morning that it has raised £50m from a group of investors including Woodford Patient Capital. One website is saying that WPCT’s share was £10m. From Atom’s news page: “Atom bank, the UK’s first bank built exclusively for mobile and the UK’s […]

12 Jul 2019 2 min read

Woodford watch – Proton again

Woodford watch – Proton again – Last Friday we wrote a short piece on Woodford Patient Capital’s largest investment, Proton Partners International. When we were researching this, one thing popped up that looked odd to us. Proton’s admission document said that Woodford got a £1m commission for entering into the commitment (in the form of […]

10 Jul 2019 1 min read

Woodford Watch – Benevolent AI

Woodford Watch – Benevolent AI Over the last couple of days, following an article in the Sunday Times (behind a paywall so we haven’t linked to it), the talk has been of a fundraise for Benevolent AI at a substantial discount to the valuation that Woodford Patient Capital (WPCT) is holding it in its NAV. […]

05 Jul 2019 2 min read

Woodford Watch – Proton Partners

Woodford Watch – Proton Partners This morning the talk on Woodford Patient Capital seems to be centred around Proton Partners. This was quite a significant holding (7.8% of gross asset value) within Woodford Patient Capital when it last disclosed its list of holdings. Now it looks as though it may be its largest investment. Proton […]

28 Jun 2019 4 min read

Woodford board wakes up

Woodford board wakes up – After weeks of virtual radio silence, the Woodford Patient Capital board has started to make some concrete plans for the future, although along the way it has lost one of its directors. On gearing WPCT has a borrowing facility for up to £150 million and on 26 June 2019, approximately £126.0 […]

10 Jun 2019 2 min read

Woodford Patient Capital board statement

Woodford Patient Capital board statement – the board of Woodford Patient Capital has released a statement this morning. Here it is: The board of Woodford Patient Capital Trust plc (the “Company”) notes the recent developments at Woodford Investment Management Ltd. Following the events relating to LF Woodford Equity Income Fund (“WEIF”), the board also notes […]

04 Jun 2019 1 min read

Woodford EI suspension places WPCT in spotlight

Woodford EI suspension places WPCT in spotlight The suspension of dealing in Neil Woodford’s open-ended Equity Income Fund – in the face of a wave of redemptions by instututions – has had a knock on effect on the fund manager’s listed entity Woodford Patient Capital, despite the investment trust being ostensibly unaffected by the move. […]

2 min read

Woodford: implications for Patient Capital

Woodford: implications for Patient Capital Dealing has been suspended on LF Woodford Equity Income, the £3.7bn open-ended flagship fund managed by Neil Woodford. It seems likely that a substantial proportion of that fund will be redeemed and it may be closed. Woodfod Patient Capital holds many investments in common with the open ended fund. If […]

05 Apr 2019 2 min read

Woodford Patient Capital discount widens despite NAV growth

Woodford Patient Capital discount widens despite NAV growth – Woodford Patient Capital, which mainly invests in early-stage unquoteds, delivered an NAV return of 6.9% in 2018, with several of its more mature holdings potentially being able to seek a listing. The shares performed less well as the discount increased by 8.4% to 15.9% at year-end. […]

02 Apr 2019 2 min read

Syncona/Woodford investment Autolus reports positive data

Syncona/Woodford investment Autolus reports positive data – Claire Roddie MB, PhD, FRCPath, honorary senior lecturer, Cancer Institute, University College London, has presented initial data from the ongoing Phase 1/2 trial of AUTO1 in adult acute lymphoblastic B cell leukemia (ALL). the presentation was made at the American Association of Cancer Research Annual Meeting 2019 in Atlanta, […]

19 Nov 2018 2 min read

Woodford Patient Capital updates on three investments

Woodford Patient Capital updates on three investments – has released some news on Immunocore, Mission Therapeutics and Spin Memory. Immunocore Immunocore has entered into a new partnership with Genentech, part of the Roche Group, to expand an existing discovery collaboration. As part of the agreement, Genentech will pay Immunocore $100 million in upfront and near-term […]

21 Sep 2018 1 min read

Woodford Patient Capital writes up value of Industrial Heat

Woodford Patient Capital writes up value of Industrial Heat – Woodford Patient Capital has added 8p to its NAV by writing up the value of Industrial Heat by 357%. This is now valued at $112.9m, which represents an increase of 8.02p per share of WPCT compared to the NAV published on Thursday 20 September 2018, […]

10 Sep 2018 2 min read

Crystal Amber reports on a good year

Crystal Amber reports on a good year – The activist fund, Crystal Amber (CRS) has delivered its full annual report for the year ending 30 June 2018. Positive performance The NAV per share rose by 19.7% over the reporting period. NAV total return for the year was 22.8%. This compares well when compared with the performance of the reference benchmark, the Numis […]

30 Aug 2018 2 min read

IP Group-backed Genomics raises £25m in a Series B

IP Group-backed Genomics raises £25m in a Series B Genomics plc, a University of Oxford spin-out backed by UK-based healthcare/tech VC investor IP Group (LSE: IPO), has closed a £25.0m Series B financing round led by the major US biotech, Vertex Pharmaceuticals. Woodford Investment Management – manager of the Woodford Patient Capital Trust (WPCT) – Invesco Perpetual, Oxford […]

22 Aug 2018 2 min read

WPCT takes profits on Autolus post IPO share price rise

WPCT takes profits on Autolus post IPO share price rise Woodford Patient Capital Trust (WPCT) appears to have taken some profits on its investment in the high-flying second generation CAR-T therapy company, Autolus Therapeutics, through a partial sale of its recently-boosted stake, according to an analysis of trust’s shareholdings in July reported this morning. This is […]

21 Aug 2018 1 min read

WPCT-backed Immunocore enters Phase I with lead GSK project

WPCT-backed Immunocore enters Phase I with lead GSK project Woodford Patient Capital Trust (WPCT)-backed Immunocore has started a Phase I study of IMCnyeso, the lead engineered T cell product under its collaboration with GlaxoSmithKline (GSK), for a range of cancers. The 63-patient Phase I/II study will assess ImmTAC in patients with non-small cell lung cancer (NSCLC), […]

16 Aug 2018 1 min read

WPCT avoids losses on Woodford backed Abzena

WPCT avoids losses on Woodford-backed Abzena Woodford Investment Management will have to take a second painful hit on one of its major biotech investments in less than a week, after the UK-based drug discovery services company Abzena agreed to a low-ball private equity takeout today after seeing a sustained share price decline. This deal follows the […]

14 Aug 2018 2 min read

WPCT set to record £33m gain on Sensyne Health

WPCT set to record £33m gain on Sensyne Health IPO Woodford Patient Capital Trust (WPCT) looks set to record a £33m gain and a 45x return on its original shareholding in the UK healthcare AI firm Sensyne Health, as a result of the company’s IPO on the London stock exchange. Sensyne, which was founded and […]

10 Aug 2018 1 min read

Woodford finally closes chapter on failed Vernalis investment

Woodford finally closes chapter on failed Vernalis investment Neil Woodford’s eponymous Patient Capital Trust (WPCT) will have to look forward to receiving just £1.8m for the 30.6m shareholding – acquired in 2015 for £18.5m – in Vernalis, the UK biotech whose failed endeavour to break into the US cough/cold market led to it being put up […]

07 Aug 2018 1 min read

Investment Trust Insider on Syncona

Investment Trust Insider on Syncona James Carthew: the problem with Syncona’s big premium Regular readers of this column will have realised that I often have as much of a problem with investment trusts trading on very high premiums as I do with trusts trading on very wide discounts. I explained a couple of weeks ago […]

03 Aug 2018 1 min read

Tekla Healthcare top specialist fund performer in July

Tekla Healthcare top specialist fund performer in July Tekla Healthcare Opportunities, a US closed end fund that invests largely in US large cap pharma and biotech, saw the best investment performance of the 14 specialist biotech specialist investors monitored by Marten & Co, in terms of its sterling-adjusted NAV performance for the month of July. Switzerland’s BB […]

2 min read

Arix remains highly geared to Autolus value

Arix remains highly geared to Autolus value Arix Bioscience’s 8% investment in Autolus Therapeutics (Nasdaq: AUTL), the recently floated second-generation CAR-T company, now accounts for more than half of the value of its investments, some 25% of its NAV and almost 30% of its stockmarket value, according to calculations by Marten & Co. Arix is by far […]

24 Jul 2018 1 min read

Autolus jumps to top of Woodford Patient Capital

Autolus jumps to top position in Woodford Patient Capital Trust Woodford Patient Capital Trust (WPCT)’s stake in Autolus, the UK second generation CAR-T therapy company, rose by six places to top position in the portfolio in June, according to WPCT’s latest factsheet. The rise reflects Autolus’ recent IPO, which was priced at a valuation considerably above […]

05 Jul 2018 2 min read

Autolus IPO boosts WPCT to top of specialist trust league in June

Autolus IPO boosts WPCT to top of specialist trust league in June The Nasdaq float of Autolus, one its top ten investee companies, boosted Woodford Patient Capital Trust (WPCT) to top position in the performance league table of biotech/healthcare specialist investment trusts for the month of June, both in terms of price and NAV total return. […]

25 Jun 2018 2 min read

Arix, Syncona and WPCT bank gains after Autolus “pops” on Nasdaq IPO

Arix, Syncona and WPCT bank gains after Autolus “pops” on Nasdaq IPO Arix Bioscience (ARIX), Syncona (SYNC) and Woodford Patient Capital Trust (WPCT) should be able to record some sizeable NAV gains this month, as previously highlighted in earlier Quoteddata.com articles, on the back of a revaluation to market value of their respective holdings in the common portfolio […]

21 Jun 2018 2 min read

US biotech IPO market faces key test after record five pricings

US biotech IPO market faces key test after record five pricings The currently buoyant US market for biotech new issues faces a key test, after a record five companies priced Nasdaq offerings in a single day. The success of those listings in the immediate after-market is likely to be important gauge of the overall health […]

20 Jun 2018 2 min read

WPCT still at bottom of bio specialist trust league in May

WPCT still at bottom of bio specialist trust league in May Neil Woodford’s eponymous Patient Capital Trust (WPCT) has once again ranked at the bottom of the performance league table of biotech/healthcare specialist investment trusts maintained by Marten & Co in the month of May, both in terms of price and NAV total return. This is […]

14 Jun 2018 1 min read

Arix, Syncona and WPCT look set to reap gains on pending Autolus IPO

Arix, Syncona and WPCT look set to reap gains on pending Autolus Nasdaq IPO Three LSE-listed health/biotech venture capital investment firms – Arix Bioscience (ARIX), Syncona (SYNC) and Woodford Patient Capital Trust (WPCT) – should see a nice boost to their NAV if Autolus, the UK-based CAR-T cell company completes its proposed Nasdaq IPO. Autolus is a portfolio company for […]

22 May 2018 1 min read

WPCT sees £43m drop in value of Prothena stake

WPCT sees £43m drop in value of Prothena stake value Woodford Patient Capital Trust (WPCT) lost £43m on its investment in Prothena last month, following the failure of the company’s NEOD001 for AL amyloidosis, according to an analysis of its portfolio by Marten & Co. Having for some time last year been WPCT’s largest investment, […]

10 May 2018 2 min read

Prothena drags WPCT to bottom of performance league table in April

Prothena drags WPCT to bottom of performance league table in April The fall in the value of its large investment in Prothena on negative results from two late-stage trials last month had a predictable effect on Woodford Patient Capital (WPCT)’s performance among the biotech-specialist closed end funds this year, although its relative underperformance extends over […]

23 Apr 2018 2 min read

Prothena blow-up leaves Woodford Patient Capital reeling

Prothena blow-up leaves Woodford Patient Capital reeling Neil Woodford’s controversial and high-profile investment in Prothena (NASDAQ:PRTA) and its development programme for AL Amyloidosis has failed, costing the Woodford Patient Capital Investment Trust (WPCT) an estimated £50m based on the average $40/share acquisition cost of its large shareholding. Prothena’s US-listed stock has fallen by 68% this […]

20 Apr 2018 2 min read

WPCT investors nervously await key Prothena data readout

WPCT investors nervously await key Prothena data readout Investors in Woodford Patient Capital Trust (WPCT) should watch for a key data readout from US-listed but Ireland-based Prothena (NASDAQ:PRTA) expected anytime in the next few weeks, which could potentially add up to 5% to the value of the trust in event of a positive result but reduce […]

03 Apr 2018 3 min read

WPCT gets surprise boost up trust leaguetable from Prothena deal

WPCT gets surprise boost up trust leaguetable from Prothena deal An unexpected recovery in Woodford Patient Capital Trust (WPCT)’s share price last month on the back of the collaboration signed between investee Prothena (NASDAQ:PRTA) and Celgene (NASDAQ:CELG), has made the struggling investment trust the surprise top performer among the sector specialist funds in March, albeit amid […]

21 Mar 2018 3 min read

WPCT gets boost from Prothena-Celgene deal

WPCT gets boost from Prothena-Celgene deal Shares in Woodford Patient Capital Trust (WPCT) have risen by almost 10% this morning to 78p on news of a partnership announced after US markets closed last night between its largest investee company, Prothena (NASDAQ:PRTA) and Celgene (NASDAQ:CELG). The partnership will develop new therapies for neurodegenerative disease, including Alzheimer’s, and […]

20 Mar 2018 2 min read

WPCT should see benefit from Oxford Nanopore fundraising

WPCT should see benefit on Oxford Nanopore fundraising Neil Woodford-managed Woodford Patient Capital Trust (WPCT) has finally generated something positive for its long suffering investors, with the fund likely to be able to take a roughly £8m fair value gain on its holding in Oxford Nanopore, following a new £100m fundraising by its UK-based investee […]

06 Mar 2018 2 min read

UK Life science VC investors cheer planned IPO of Autolus

UK Life science VC investors cheer planned IPO of Autolus Three high-profile UK life science investors – Syncona (SYNC), Arix Bioscience (ARIX) and Woodford Patient Capital Trust (WPCT) – could benefit from the possible US IPO of the engineered T-cell therapy company, Autolus, following that company’s disclosure yesterday of a filing of a confidential draft F1 submission. All three investors hold […]

02 Mar 2018 2 min read

Swiss trusts top performers among bio sector specialists in Feb

Swiss trusts top performers among bio sector specialists in Feb – Switzerland’s HBM Healthcare Investments (HBMN.S) and BB Biotech (BBB.S) were the best performing biotech/pharma specialist investment trusts in February and indeed were the only ones of the 13 monitored by Marten & Co to have recorded any increase in NAV (in sterling terms) in the month. However, […]

22 Feb 2018 2 min read

WPCT sees small decline in Jan NAV but greater share price fall

WPCT sees small decline in Jan NAV but greater share price fall Struggling Neil Woodford-managed Woodford Patient Capital Trust (WPCT) reported a small, ~0.6% decline in NAV in January, but has since seen a larger 11% decline in share price this month as investors have become increasingly concerned about its poor long-term performance and outlook. The decline […]

09 Feb 2018 2 min read

Swiss biotech trusts resilient after recent sell-off

Swiss biotech trusts resilient after recent sell-off – Swiss-listed biotech investment trusts, HBM Healthcare Investments (HBMN.S) and BB Biotech (BBB.S), have fared by far the best among all the sector specialist closed-end collective vehicles in the wake of the global market sell-off in recent days. All 13 trusts in the group monitored by Marten & Co have seen a fall […]

23 Jan 2018 2 min read

HBM Healthcare tops biotech trust league in 2017

HBM Healthcare tops biotech trust league in 2017 Swiss-listed HBM Healthcare Investments (HBMN.S) can claim to have been the best performing biotech-specialist closed-end fund in 2017, according to an analysis by Marten & Co. The CHF1.1bn trust run by Swiss healthcare investment specialist HBM saw its share price rise from CHF99 to CHF134 last year […]

22 Dec 2017 2 min read

Prothena drag on Woodford Patient Capital

Prothena drag on Woodford Patient Capital A 45% fall in the value of its large shareholding in Prothena since the end of the third quarter seems to have been the main factor behind a decline in the value of Woodford Patient Capital Trust (WPCT) over the same period, according to the trust’s latest monthly update. WPCT’s shares have […]

18 Dec 2017 1 min read

Investment Trust Insider on Biotech

Investment Trust Insider on Biotech – inspired by the launch of our biotech news service on QuotedData, I wrote something for Citywire that looks at some of the exciting stories that have been published just in the last couple of weeks. James Carthew: biotech boom boosts generalist trusts This week I am returning to the […]

2 min read

US analysts target Woodford Patient Capital investees

US analysts target key Woodford Patient Capital investees The Neil Woodford-managed biotech/tech investment trust, Woodford Patient Capital Trust (WPCT), is finding itself under increasing pressure, with analysts at two separate US firms calling into question its two largest investments, Prothena (15.6% of NAV at 30 September ) and Oxford Nanopore (8.9%). Ireland-based but Nasdaq-listed Prothena […]

12 Dec 2017 1 min read

UK CAR-T firm Autolus provides update at ASH conference

UK CAR-T firm Autolus provides update at ASH conference Autolus, which is a closely-watched chimeric antigen receptor T-cell therapy firm backed by three of the UK’s most prominent biotech investors, obtained an important validation of its technology recently with the publication of data on its dual targeting technology at the American Society of Hematology (ASH) conference over […]

12 Sep 2017 1 min read

Investment Trust Insider on The People’s Trust

The People’s Trust, Daniel Godfrey’s long-trailed investment trust, launched its initial public offer (IPO) on Friday. It is aiming to raise £125 million. The fund intends to produce ‘better returns for you and a better impact on society’. There won’t be a huge dividend, a yield of about 1.8% is forecast, and this may curb […]

31 Jul 2017 3 min read

Better year for Growth pool in F&C Managed Portfolio

Better year for Growth pool in F&C Managed Portfolio – F&C Managed Portfolio has published results for the year ended 31 May 2017. The NAV total return (i.e. adding dividends paid to capital performance) was 24.5% for the Income shares and 26.4% for the Growth shares. This compares with the 24.5% total return for the All-Share […]

21 Apr 2017 2 min read

More patience required for Woodford Patient Capital shareholders

Woodford Patient Capital says that 2016 was a challenging year, with its net asset value declining modestly from 97.37p to 93.24p. Meanwhile, the share price moved from a 3.7 per cent premium to net asset value at the end of 2015, to a slight discount of -2.4 per cent at the end of the period, […]

15 Nov 2016 1 min read

Woodford investment trust gets Trump boost

The Woodford Patient Capital trust has enjoyed a 4 per cent boost to its NAV following the election of Donald Trump to the White House. The Woodford fund was among the top-10 investment trusts on the day after the US election, with many of the best performing being focussed on biotech. read more here

14 Nov 2016 1 min read

Why Neil Woodford is celebrating a Trump victory

I don’t know whether fund management legend Neil Woodford was in favour of Trump or Clinton, or wished a plague on both their houses, and nor do I care (writes Harvey Jones of Motley Fool). However, Donald Trump’s shock victory has given Mr Woodford something to celebrate, by applying much-needed balm to his Achilles’ heel. read more […]

08 Nov 2016 1 min read

Woodford trust falls into worst performers list in October

The £733m Woodford Patient Capital trust appeared in the top ten worst performing funds in NAV terms in October according to the latest research from investment company analysts QuotedData. The trust, ran by star manager Neil Woodford, was down 5.1% for the month, making it the fifth worst performing fund in NAV terms in the […]

06 Oct 2016 1 min read

If it is good enough for Neil Woodford… peer-to-peer trusts can yield up to 10% – but are they worth the risk?

In today’s low interest rate world, investment trusts are struggling to match the income payouts they have maintained in recent years. Read more: http://www.thisismoney.co.uk/money/diyinvesting/article-3813416/Peer-peer-investment-trusts-offer-yields-10-worth-risk.html#ixzz4MJTrYHYS

04 Aug 2016 4 min read

Woodford Patient Capital beefs up board after disappointing H1

Woodford Patient Capital says its portfolio declined in value by 10.8 per cent over the first half of 2016 and the company’s shares ended the period at a modest discount of 3.1 per cent. Two new non-executive directors have been brought onto the Board following consultation with shareholders. The new non-executive directors have specific investment trust experience. […]

05 Jul 2016 1 min read

Crystal Amber asks for sale of Northgate

On 4 July 2016, it was disclosed that Crystal Amber Fund Limited had acquired a disclosable interest of 3 per cent of the issued share capital of Northgate. In September 2012, Crystal Amber invested in Northgate and following successful engagement, exited the position in April 2015. Since then, Northgate’s share price has fallen by approximately 50%. […]

21 Jun 2016 1 min read

Woodford comments on Circassia

In its latest blog, Woodford Patient Capital has commented on the dramatic fall in the price of its largest investment, Circassia. You can read the blog in full here. “[Circassia] has this morning announced the failure of its high-profile phase III study into its cat allergy vaccine. This is undoubtedly a disappointing development. We had high […]

22 Mar 2016 2 min read

Woodford Patient Capital suspends fund raising

Woodford Patient Capital has published its first set of results covering the period from incorporation through its launch in April last year and finishing on 31 December 2015. The net asset value of Woodford Patient Capital Trust ended the period at 97.38p per share (cum income), slightly below the issue price of 100p per share. […]

13 Jan 2016 1 min read

Woodford Patient Capital is considering raising further capital

Woodford Patient Capital Trust, managed by Neil Woodford (pictured), has provided an update to investors which advises that the trust has now deployed the proceeds from its IPO (the trust listed on the LSE in April 2015 raising £800m) and that it has a substantial ongoing pipeline of investment opportunities. The company says that, with […]

03 Dec 2015 1 min read

Woodford Patient Capital’s Purplebricks to list on AIM

Online estate agency, Purplebricks, has announced that it has conditionally raised £58.1m before expenses from an institutional placing for its upcoming float on AIM. The company, which is expected to list on 17 December, is expected to have an opening market capitalisation of £240.3m. Woodford Patient Capital Trust, managed by Neil Woodford (pictured) has an investment […]

24 Nov 2015 2 min read

BACIT backed Woodford fund

BACIT Limited has announced interim results for the six months ended 30 September 2015. The return on net assets for the period was -3.28% which compares to -7.19% for the FTSE All-Share Index and -6.78% for the HFRI Fund of Funds Strategic Index. Looking at the portfolio: Equity Funds (24.9% at 30 September 2015 vs. […]

11 Aug 2015 2 min read

Woodford Patient Capital unveils its portfolio

Woodford Patient Capital has published its first set of figures – interims covering the period from its launch until the end of June 2015. The net asset value at the end of the period was 101.86p and the share price 113.5p – putting it on a premium of 11.4%. The Board is planning to issue […]

22 Jul 2015 1 min read

Discount trends, big names big prices

http://www.moneyobserver.com/news/21-07-2015/discount-trends-big-names-big-prices Investment trusts with big name managers saw their share prices soar over the second quarter as investors sought out the best active management.

20 Jul 2015 1 min read

Investment trusts see largest ever new issue

QuotedData reports that the investment trust sector expanded by about GBP2.4 billion over the second quarter of 2015, taking in close to GBP2.9 billion and handing back just over GBP450 million. The firm comments that many of the funds raising money are not designed to throw off high levels of income, suggesting that investors are […]

Schroders Capital Global Innovation Trust : INOV

Overview

Fundamentals

Price

Research History

QuotedData’s Investment Companies Quarterly Review – First quarter of 2024

QuotedData’s Investment Companies Quarterly Review – Third Quarter 2023

QuotedData’s Investment Companies Roundup – October 2023

QuotedData’s Investment Companies Quarterly Review – Third Quarter 2022

Interview with Tim Creed from Schroder UK Public Private

QuotedData’s Spring Webinar Series – Private Equity playback

QuotedData’s Growth Strategies Conference – playback

QuotedData’s Investment Companies Quarterly Review – Second Quarter 2020

QuotedData’s Investment Companies Roundup – July 2020

QuotedData’s Investment Companies Roundup – February 2020

QuotedData’s Investment Companies Annual Review – 2019

QuotedData’s investment companies roundup – January 2020

QuotedData’s investment companies roundup – December 2019

QuotedData’s investment companies roundup – November 2019

Investment companies quarterly roundup – Third quarter 2019

QuotedData’s investment companies roundup – October 2019

QuotedData’s economic roundup – October 2019

QuotedData’s investment companies roundup – September 2019

QuotedData’s investment companies roundup – August 2019

Quarterly investment companies roundup – Second quarter 2019

QuotedData’s investment companies roundup – July 2019

QuotedData’s investment companies roundup – June 2019

Quarterly Investment Companies Roundup – Third Quarter 2018

QuotedData’s investment companies roundup – October 2018

QuotedData’s investment companies roundup – September 2018

QuotedData’s investment companies roundup – July 2018

QuotedData’s investment companies roundup – May 2018

QuotedData’s investment companies roundup – April 2018

QuotedData’s investment companies roundup – March 2018

QuotedData investment companies roundup – January 2018

QuotedData investment companies roundup – December 2017

QuotedData investment companies roundup – November 2017

QuotedData investment companies roundup – September 2017

QuotedData investment companies roundup – November 2016

News

Morning briefing: Knockout bid for 89Bio boosts International Biotechnology; plus MCT, NCYF, FGEN & INOV

Morning briefing: Literacy Capital shifts to “maximising value”; Riverstone Energy shareholders back wind-up; plus WHR, BGS, INOV, BSV, BSC, CRWC, AAEV & AATG

Trust Spot: July’s biggest risers and fallers leave one 9%-yielding property fund cheap on a 19% discount

FCA fines Neil Woodford £5.9m for his fund’s 2019 collapse that left Patient Capital trust in the lurch

Investors jump at chance to sell what’s left of Woodford Patient Capital Trust

Morning briefing 11 July: ASLI, SERE, CREI, INOV, CGEO

Q&A: Should I finally sell my shares in the great Woodford wind-up, Schroders Capital Global Innovation (INOV)?

Schroder Capital Global Innovation launches tender offer

QuotedData’s morning briefing 22 May 2025 – FJV, PCGH, GRID, INOV, SERE

Schroders Capital Global Innovation begins wind-down as NAV falls 21.2%

Schroders Capital Global Innovation publishes wind down proposals

QuotedData’s morning briefing 4 December 2024 – ARR, SEIT, PNL, MNKS, INOV

QuotedData’s weekly news show 30th August 2024

Syncona backs two new cancer companies

QuotedData’s morning briefing 23 May 2024 – BGLF, CRS, INOV, IPU

Schroder Capital Global Innovation encouraged by positive Q4 move

QuotedData’s morning briefing 13 February 2024 – JGGI, TRIG, INOV, BPCR

QuotedData’s morning briefing 9 February 2024 – INOV, RTW, ADIG

QuotedData’s morning briefing 5 February 2024 – CVCE, INOV, PEY, GSF, HGT, SEIT

Schroders Capital Global Innovation’s Carmot Therapeutics sold to Roche

QuotedData’s morning briefing 4 December 2023 – GSF, SEQI, SYNC, SBO, INOV, IGC, JLEN, SEIT

QuotedData’s morning briefing 20 November 2023 – SSIT, INOV, IBT, USF, UKCM

QuotedData’s morning briefing 15 November 2023 – GCP, FP, INOV, WHR

Schroder Cap Global Innovation backs Bizongo

QuotedData’s morning briefing 3 November 2023 – INOV

Schroders Capital Global Innovation NAV dives again

QD view – Where there’s smoke is there fire?

QD view – AI mania driving tech recovery

QuotedData’s morning briefing 6 June 2023

SUPP struggles against market headwinds

Schroder UK Public Private backs Indian AgTech start-up

SBV updates from Schroder UK Public Private and Seraphim Space

QuotedData’s morning briefing 17 November 2022

QuotedData’s morning briefing 4 November 2022

Schroder UK Public Private Trust invests in antibody drug firm

QuotedData’s morning briefing 30 September 2022

QuotedData’s morning briefing 21 September 2022

QuotedData’s morning briefing 27 April 2022

Schroder UK Public Private considers going global

QuotedData’s morning briefing 5 April 2022